Search results for "Boronic Acids"

showing 10 items of 26 documents

Investigation of fungicidal activity of 3-piperazine-bis(benzoxaborole) and its boronic acid analogue

2014

3-Piperazine-bis(benzoxaborole) and its bis(phenylboronic acid) analogue were investigated in terms of their fungicidal activity. The study was carried out against five filamentous fungi: Aspergillus terreus, Fusarium dimerum, Fusarium solani, Penicillium ochrochloron and Aspergillus niger. 3-Piperazine-bis(benzoxaborole) revealed higher inhibitory activity towards the examined strains than standard antibiotic (amphotericin B), whereas bis(phenylboronic acid) proved to be inactive. The study unequivocally showed that the presence of the heterocyclic benzoxaborole system is essential for antifungal action of the examined compounds.

fungicidal activitybenzoxaborolesboronic acidsfungicidesApplied Organometallic Chemistry
researchProduct

Bortezomib: a new pro-apoptotic agent in cancer treatment.

2010

Bortezomib is a proteasome inhibitor. It targets the ubiquitin-proteasome pathway with subsequent inhibition of the degradation of proteins involved in cell cycle regulation and cancer cell survival. The best known molecular mechanism concerns the inhibition of IkappaB breakdown and the related stabilization of NFkappaB, thus preventing its translocation to the nucleus for the activation of downstream pathways. Bortezomib is the only drug in this class which has been approved for clinical use. It has shown an efficient antitumor effect in a phase III clinical trial (APEX) involving relapsed multiple myeloma patients. Response rate, time to progression and overall survival have been improved…

Cancer ResearchCell cycle checkpointSettore MED/06 - Oncologia MedicaAntineoplastic AgentsApoptosisPharmacologyDexamethasoneBortezomibMiceNeoplasmshemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsDrug DiscoverymedicineAnimalsHumansDexamethasoneMultiple myelomaPharmacologyproteasome inhibitionClinical Trials as TopicNeovascularization Pathologicbusiness.industryBortezomibCell CycleNF-kappa Bsolid tumorsmedicine.diseaseBoronic AcidsClinical trialBortezomib; solid tumors; proteasome inhibition.OncologyApoptosisPyrazinesCancer cellProteasome inhibitorCancer researchMultiple MyelomabusinessProteasome InhibitorsBortezomib solid tumors proteasome inhibitionmedicine.drug
researchProduct

Antifungal activity and tautomeric cyclization equilibria of formylphenylboronic acids

2019

2-Formylphenylboronic acid and four isomeric fluoro-2-formylphenylboronic acids have been found active against a series of fungal strains: Aspergillus, Fusarium, Penicillium and Candida. The level of antifungal activity was evaluated by agar diffusion tests as well as the determination of minimum inhibitory concentrations (MICs) by serial dilution method. Among the tested compounds, 4-fluoro-2-formylphenylboronic acid - an analogue of the known antifungal drug Tavaborole (AN2690) - proved to be the most potent antifungal agent. The tautomeric equilibrium leading to the formation of 3-hydroxybenzoxaboroles as well as the position of the fluorine substituent were revealed to play a crucial ro…

Antifungal Agentsfood.ingredientSerial dilutionStereochemistryAntifungal drugSubstituentMicrobial Sensitivity TestsFormylphenylboronic acid01 natural sciencesBiochemistryStructure-Activity Relationshipchemistry.chemical_compoundfoodFusariumDrug DiscoveryAgarAntifungal activityTautomerizationMolecular BiologyCandidaAspergillusTavaboroleDose-Response Relationship DrugMolecular Structurebiology010405 organic chemistryChemistryOrganic ChemistryPenicilliumCyclization equilibriaOrganoboron compoundsbiology.organism_classificationBoronic AcidsTautomer0104 chemical sciences010404 medicinal & biomolecular chemistryAspergillusCyclizationPenicilliumBioorganic Chemistry
researchProduct

Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma

2013

Abstract Background A combination of bortezomib (1.3 mg/m2), melphalan (5 mg/m2), and dexamethasone (40 mg) (BMD), with all three drugs given as a contemporary intravenous administration, was retrospectively evaluated. Patients and methods Fifty previously treated (median 2 previous lines) patients with myeloma (33 relapsed and 17 refractory) were assessed. The first 19 patients were treated with a twice-a-week (days 1, 4, 8, 11, ‘base’ schedule) administration while, in the remaining 31 patients, the three drugs were administered once a week (days 1, 8, 15, 22, ‘weekly’ schedule). Results Side-effects were predictable and manageable, with prominent haematological toxicity, and a better tox…

AdultMaleMelphalanmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsSalvage therapyGastroenterologyDexamethasoneDisease-Free SurvivalDrug Administration ScheduleBortezomibRefractoryRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalMelphalanMultiple myelomaDexamethasoneAgedRetrospective StudiesAged 80 and overBortezomibbusiness.industryHematologyMiddle Agedmedicine.diseaseBoronic AcidsRegimenTreatment OutcomeOncologyPyrazinesInjections IntravenousFemaleMultiple MyelomabusinessFollow-Up Studiesmedicine.drug
researchProduct

JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways

2006

The proteasome inhibitor bortezomib is an efficacious apoptotic agent in many tumor cells. This paper shows that bortezomib induced apoptosis in human hepatoma HepG2 cells associated with many modifications in the expression of survival or death factors. Although bortezomib increased the level of the protective factors HSP70 and HSP27, the effects of the drug that favour cell death were predominant. These events include accumulation of c-Jun, phospho-c-Jun and p53; increase in FasL level with activation of caspase-8; changes related to members of Bcl-2 family with increase in the level of pro-apoptotic members and decrease in that of anti-apoptotic ones; dissipation of mitochondrial potenti…

Cancer ResearchProgrammed cell deathFas Ligand ProteinProto-Oncogene Proteins c-junClinical BiochemistryPharmaceutical ScienceAntineoplastic AgentsApoptosisCaspase 8Cell LineBortezomibHsp27Cell Line TumormedicineHumansMitogen-Activated Protein Kinase 8Protease InhibitorsAP1Heat-Shock ProteinsPharmacologyCaspase 8Membrane GlycoproteinsbiologyJNK.Bortezomibc-JunLiver NeoplasmsBiochemistry (medical)c-junhepatomaCell BiologyapoptosiBoronic AcidsMitochondriaCell biologyTranscription Factor AP-1AP-1 transcription factorLiverProto-Oncogene Proteins c-bcl-2ApoptosisCaspasesPyrazinesTumor Necrosis Factorsbiology.proteinCancer researchProteasome inhibitorSignal Transductionmedicine.drugApoptosis
researchProduct

Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.

2007

The ubiquitin-proteasome pathway is the main proteolytic system present in the nucleus and cytoplasm of all eukaryotic cells. Apoptosis activation induced by ubiquitin-proteasome pathway inhibition makes the proteasome a new target of anticancer therapy. Bortezomib is the first proteasome inhibitor to be approved by the US FDA; in 2003 as a third line and in 2005 as a second line therapy for the treatment of multiple myeloma only. This review focuses on the use of bortezomib, not only in its therapeutic role but also, more specifically, in its biologic role and discusses the most recent applications of the drug in solid tumors, both at a preclinical and clinical level.

Drugubiquitin-proteasome pathway proteasome inhibitorsSettore MED/06 - Oncologia Medicamedia_common.quotation_subjectClinical BiochemistryDrug Evaluation PreclinicalAntineoplastic AgentsApoptosisPharmacologyBortezomibNeoplasmsDrug DiscoverymedicineAnimalsHumansMultiple myelomamedia_commonPharmacologyClinical Trials as Topicbusiness.industryBortezomibmedicine.diseaseBoronic AcidsProteasomeClinical evidenceCytoplasmApoptosisPyrazinesProteasome inhibitorMolecular Medicinebusinessmedicine.drug
researchProduct

Novel 2,6-disubstituted phenylboronic compounds - Synthesis, crystal structures, solution behaviour and reactivity

2015

Abstract 2,6-Diformylphenylboronic acid has been synthesized and characterized both in the solid state as well as in solution. In crystal, an unusual structural pattern has been found with the formation of intermolecular hydrogen bonds by B(OH) 2 and CHO groups as well as water molecules. In solution tautomeric equilibrium with the formation of oxaborole ring by one of the formyl groups was proved on the basis of multinuclear NMR spectroscopy. The title compound reacts with secondary mono- and diamines to form various types of substituted benzoxaboroles, which have been characterized by XRD and spectroscopic methods.

crystal structureboronic acidsChemistryHydrogen bondOrganic ChemistryCrystal structureNuclear magnetic resonance spectroscopyRing (chemistry)BiochemistryTautomerreductive aminationtautomeric equilibriaInorganic ChemistryCrystalbenzoxaborolesPolymer chemistryMaterials ChemistryMoleculeReactivity (chemistry)Physical and Theoretical ChemistryJournal of Organometallic Chemistry
researchProduct

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.

2018

© 2018 The Authors.

MaleCancer ResearchBoronic Acid[SDV]Life Sciences [q-bio]bortezomib ; global ; observational study ; routine practice ; stem cell transplantationSalvage therapyPractice PatternsDexamethasoneBortezomibRoutine practice0302 clinical medicineBortezomib; Global; Observational study; Routine practice; Stem cell transplantationhemic and lymphatic diseasesObservational studyAntineoplastic Combined Chemotherapy Protocols80 and overProspective StudiesPractice Patterns Physicians'Prospective cohort studyLenalidomideComputingMilieux_MISCELLANEOUSMultiple myelomaAged 80 and overBortezomibStem cell transplantationGlobalHematologyMiddle AgedBoronic Acids3. Good healthThalidomideSurvival RateTreatment OutcomeLocalOncology030220 oncology & carcinogenesisBortezomib; Global; Observational study; Routine practice; Stem cell transplantation; Hematology; Oncology; Cancer ResearchFemaleMultiple MyelomaBortezomib; Global; Observational study; Routine practice; Stem cell transplantation; Adult; Aged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence Local; Prospective Studies; Survival Rate; Thalidomide; Treatment Outcome; Practice Patterns Physicians'; Salvage Therapymedicine.drugHumanAdultmedicine.medical_specialty/NOFollow-Up Studie03 medical and health sciencesInternal medicinemedicineHumansSurvival rateLenalidomideAgedSalvage TherapyPhysicians'Antineoplastic Combined Chemotherapy Protocolbusiness.industrySettore MED/15medicine.diseaseTransplantationThalidomideSettore MED/15 - MALATTIE DEL SANGUEProspective StudieNeoplasm RecurrenceNeoplasm Recurrence Localbusiness030215 immunologyFollow-Up StudiesClinical lymphoma, myelomaleukemia
researchProduct

Enantioselective Palladium-Catalyzed Oxidative β,β-Fluoroarylation of α,β-Unsaturated Carbonyl Derivatives

2016

© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim The site-selective palladium-catalyzed three-component coupling of deactivated alkenes, arylboronic acids, and N-fluorobenzenesulfonimide is disclosed herein. The developed methodology establishes a general, modular, and step-economical approach to the stereoselective β-fluorination of α,β-unsaturated systems.

Reaction mechanismHydrocarbons FluorinatedHalogenationStereochemistrychemistry.chemical_elementStereoisomerismAlkenes010402 general chemistry01 natural sciencesArticleCatalysisCatalysisFluorinatedfluorineOrganic chemistrychemistry.chemical_classificationSulfonamidesMolecular StructurealkenesAlkene010405 organic chemistryOrganic ChemistryEnantioselective synthesisHalogenationStereoisomerismGeneral ChemistryGeneral MedicinepalladiumBoronic AcidsHydrocarbons0104 chemical sciencesreaction mechanismschemistryChemical Sciencessynthetic methodsStereoselectivityOxidation-ReductionPalladiumPalladium
researchProduct

(Trifluoromethoxy)Phenylboronic Acids: Structures, Properties, and Antibacterial Activity.

2021

Three isomers of (trifluoromethoxy)phenylboronic acids were studied in the context of their physicochemical, structural, antimicrobial and spectroscopic properties. They were characterized by 1H, 13C, 11B and 19F NMR spectroscopy. The acidity of all the isomers was evaluated by both spectrophotometric and potentiometric titrations. The introduction of the -OCF3 group influences the acidity, depending, however, on the position of a substituent, with the ortho isomer being the least acidic. Molecular and crystal structures of ortho and para isomers were determined by the single crystal XRD method. Hydrogen bonded dimers are the basic structural motives of the investigated molecules in the sol…

Models MolecularMagnetic Resonance SpectroscopyPotentiometric titrationSubstituentMolecular ConformationPharmaceutical ScienceContext (language use)Crystal structureMicrobial Sensitivity TestsDFTMedicinal chemistryArticleOCF<sub>3</sub>Analytical Chemistrylcsh:QD241-441chemistry.chemical_compoundlcsh:Organic chemistryDrug StabilityIsomerismtrifluoromethoxyDrug DiscoveryMoleculePhysical and Theoretical ChemistryMolecular StructureHydrogen bondOrganic ChemistryBoronic AcidsNMRAnti-Bacterial AgentsantibacterialchemistryChemistry (miscellaneous)Intramolecular forceX-RayMolecular MedicineisomersOCF3Derivative (chemistry)Molecules (Basel, Switzerland)
researchProduct